There are about 36818 clinical studies being (or have been) conducted in China. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Using online questionnaires, we will obtain data regarding COVID-19 infection and treatment, including incidence rate, hospitalization rate, severity of the infection, medications, mortality rate, etc, in both hospital and communities after the change of disease control policy in China.
Malnutrition caused by reduced food intake or assimilation and varying degrees of acute or chronic inflammation is a serious and underappreciated risk factor for adverse clinical outcomes. Despite the substantial health and economic burden, malnutrition remains to affect a considerable proportion of hospitalized patients worldwide. Nationally representative studies from the USA, Australia, and European countries have reported prevalence figures in the range of 8.9% to 80.4%. However, national data in some resource-poor countries, such as China, the largest developing country in the world, are scarce. During 2020 to 2022, the investigators conducted the China Nutrition Fundamental Data 2020 (CNFD 2020). This project provides a reference for nutritional risk assessment, malnutrition diagnosis, and treatment criteria for hospitalized patients in China. This project also provides data to promote the construction of clinical nutrition departments and improve the nutritional status of hospitalized patients. Thus, the investigators plan to conduct the China Nutrition Fundamental Data 2022 in a large, nationally representative sample of Chinese adult inpatients to 1) To further explore the relationship between nutrition and health; 2) To further understand the capacity of nutrition services in Chinese medical institutions. This project will adopt a multistage, stratified, cluster-sampling procedure based on administrative divisions in China. For each participant, a structured interview will be done by trained nutritionists or clinicians. The following data will be acquired: weight change within and beyond six months, food intake change within two weeks, nutrition therapy during this hospitalization, Karnofsky score, clinical outcome, total hospitalization costs, and laboratory tests. The investigators will also collect information on participants' sociodemographic characteristics and medical history. The investigators will take physical measurements, including height, weight, waist circumference, hip circumference, mid-arm circumference, calf circumference, handgrip strength, and blood pressure following standard protocols. Body composition will be measured using bioimpedance analysis (BIA). In addition, the investigators plan to collect information on the number of beds, the nutrition support team, the nutrition treatment plan and the construction of a full-time nutrition physician or nutrition nurse, the routine monitoring methods, interventions, and distribution of brochures for patients with malnutrition or nutritional risk in each project hospital.
The primary purpose of this study is to evaluate the efficacy and safety of intravenous administration at regular intervals of Ustekinumab in participants with loss of response to standard regimen or have evidence of high activity clinically, biochemically or endoscopically.
The goal of this clinical trial is to explore the therapeutic effect of pulse magnetic therapy system combined with drug therapy on patients with anxiety and insomnia. The main questions it aims to answer are: 1. Whether the pulse magnetic therapy system is benefit on improving insomnia in anxiety patients. 2. This improvement is not due to the placement of the instrument。 Participants will accept pulse magnetic therapy (stimulation/sham stimulation) and accept scale evaluation before and after treatment. Researchers will compare the pulse magnetic stimulation group, sham stimulation group and healthy controls to see if the pulse magnetic stimulation do effect on insomnia of anxiety patients.
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC responsiveness. The objective of this study is to develop and evaluate the utility of circulating exosomes as companion diagnostic biomarker for predicting response to immunotherapy in patients with RCC.
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Hypertension is an risk factor for cognitive impairment. The primary objective of this study is to evaluate the efficacy of 12-week computerized cognitive training in people with hypertension and mild cognitive impairment. The researchers will further investigate the long-term effects of cognitive training by prolonging the intervention for 24 weeks among a randomly selected sub-group.
This study aims to evaluate the impact of non-invasive CT-based Hepatic Venous Pressure Gradient (HVPG) assessment on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).